Company patents
23andMe, Inc.
23andMe, Inc. shows a surprising shift in its patent strategy, with significant declines across its core computing-related categories like Databases & Information Retrieval (down 26.7% YoY in 2025) and Machine Learning & AI (down 30.8% YoY in 2025), despite these areas representing a substantial portion of its 95-patent portfolio (54.7% and 45.3% respectively). While Bioinformatics remains its largest category at 72.6% of the portfolio, the dramatic 100% decline in patenting activity across most categories so far in 2026 suggests a potential re-evaluation or pause in its patenting efforts, with only Peptides & Proteins, Pharmaceutical Preparations, and Therapeutic Activity (Pharma) showing any activity this year, albeit with declines.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
95 US filings (since 2023) · 12 categories · 11 themes
Computational techniques and algorithms for processing, aligning, and interpreting raw biological sequence data (DNA, RNA, protein), including identifying genetic variations, classifying organisms, or predicting sequence attributes.
Applying computational methods, often involving machine learning and multiomics data, to design, analyze, and understand biomolecules, genetic sequences, or complex biological systems.
Methods and systems for integrating, transforming, and managing complex or domain-specific data from disparate sources into a unified structure, often for specific applications like social networks, genomics, or business forms.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Computational methods and systems for analyzing biological data (e.g., genomic, proteomic, clinical) to diagnose diseases, predict patient prognosis, assess treatment response, or stratify patients for therapy.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Systems that process data to provide personalized recommendations, predict events, or automate decision-making processes based on learned patterns, user behavior, or environmental factors.
Utilizing machine learning, particularly deep learning, to analyze medical data such as images, sensor readings, or physiological signals for disease prediction, diagnosis, or treatment assessment.
Methods and systems for combining and analyzing diverse biological datasets (e.g., genomics, transcriptomics, proteomics, metabolomics) to uncover complex biological relationships, disease mechanisms, or temporal trajectories.
Patents
Showing 1-10 of 80
Advanced Genomic Sequence Analysis